Introduction Executive Summary Blepharitis: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Blepharitis – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Blepharitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends Blepharitis Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis TP-03: Tarsus Pharmaceuticals • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis NCX 4251: NicOx • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Blepharitis Key Companies Blepharitis Key Products Blepharitis- Unmet Needs Blepharitis- Market Drivers and Barriers Blepharitis- Future Perspectives and Conclusion Blepharitis Analyst Views Blepharitis Key Companies Appendix

Table 1 Total Products for Blepharitis Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• NicOx • Tarsus Pharmaceuticals • AxeroVision • InSite Vision